Results 111 to 120 of about 107,880 (159)

重型肝炎患者血清肝炎病毒标志的#br# 检出及与预后的关系

, 1997
摘　要　用酶联免疫吸附试验(ELISA)和聚合酶链反应(PC R)技术对203 例重型肝炎的血清肝炎病毒标 志物进行检测, 结果显示单纯HBV 感染108 例(53 .2 %), HC V 感染6 例(2 .95 %), HEV 感染8 例(3 .94 %), HBV 和HCV 混合感染17 例(8 .37 %), HBV 和H EV 混合感染36 例(17 .73 %), 12 例(5 .91 %)未找到确切病 因, 表明HBV 感染仍是重型肝炎的最主要病因(176/ 203), 其次为HEV ...
林炳亮　杨绍基　姚集鲁
core  

[Construction of a highly efficient HBV infection cell model based on HBV co-receptor neuropilin-1]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Liu ZH, He XM, Xu KX, Yu HB, Chen J.
europepmc   +1 more source

[Characteristics and predictive factors of recompensation in patients with hepatitis B-related decompensated cirrhosis: a retrospective cohort study]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Li YJ, Yan ZL, Deng JH, Yang LP, Lu Y, Wang ZL, Lu Q, Chen JT, Xin XE, Zu HM.   +9 more
europepmc   +1 more source

[Advancement in the role of exosomes for hepatitis B virus infection diagnosis and treatment: mechanisms and clinical applications]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Du MX, Hua WT, Wan SH, Gao YT, Zhang YL, Liu JY, Zhang X.   +6 more
europepmc   +1 more source

[Construction of a predictive model for recompensation in patients with decompensated viral hepatitis-induced cirrhosis]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Xu DQ, Mu H, Sa CF, Zhang YY, Mou CY, Liu L.   +5 more
europepmc   +1 more source

[Expert recommendations on the first-line use and optimization plan of nucleos(t)ide analogues in the context of functional cure for chronic hepatitis B]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association.   +2 more
europepmc   +1 more source

肝病患者血清碱性谷胱苷肽S转移酶放射免疫测定及临床意义

Zhongshan Daxue xuebao. Yixue kexue ban, 1991
应用放射免疫测定法(RIA)检测277例肝病患者血清碱性谷胱苷肽S转移酶(B-GST),并以54例健康人及28例非肝病作对照,研究结果发现各型肝病血清B-GST均明显升高,提示B-GST是一项反映肝损害的敏感指标;它对急性肝炎的诊断意义与丙氨酸转氨酶(ALT)相若,但对反映慢性肝炎及轻微肝损害则较ALT敏感,且具有更好的肝胆特异性,还对肝炎预后及反映肝脏病理改变有较好的参考意义.
doaj  

[Effect of switching from entecavir to tenofovir amibufenamide on HBsAg levels in patients with chronic hepatitis B: a 96-week real-world study]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Wang LL, Chen J, Wang XY, Liu ZS, Yu J, Yu JQ, Zhang HF.   +6 more
europepmc   +1 more source

[Interpretation of key updates of the 2026 version of the APASL clinical practice guidelines for the management of chronic hepatitis B]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Liu HS, Ai XW, Sun YM, You H.
europepmc   +1 more source

[Expert recommendations on the management of adverse reactions in pegylated interferon alpha therapy for chronic hepatitis B]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Expert Group on the Management of Adverse Reactions in Pegylated Interferon Alpha Therapy for Chronic Hepatitis B.
europepmc   +1 more source